ARWR
Arrowhead Pharmaceuticals, Inc.
NASDAQHealthcareBiotechnologyUS
Rating:D+
Company Profile
CEO
Christopher R. Anzalone
IPO Date
1993-12-16
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
Arrowhead Pharmaceuticals, Inc.
CEO
Christopher R. Anzalone
IPO Date
1993-12-16
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
| 3,208 |
| $70.11 |
| 24 Apr 2026 | Apel Daniel Joseph | Chief Financial Officer | S-Sale | Disposed | 1,157 | $70.45 |
| 24 Apr 2026 | Apel Daniel Joseph | Chief Financial Officer | S-Sale | Disposed | 8,730 | $71.92 |
| 24 Apr 2026 | Hamilton James C | Chief Medical Officer | S-Sale | Disposed | 10,000 | $75.00 |
| 9 Mar 2026 | Hamilton James C | Chief Medical Officer | S-Sale | Disposed | 10,000 | $64.19 |
| 8 Jan 2026 | Hamilton James C | Chief Medical Officer | A-Award | Acquired | 75,000 | $0.00 |
| 8 Jan 2026 | Apel Daniel Joseph | Chief Financial Officer | A-Award | Acquired | 75,000 | $0.00 |
| 8 Jan 2026 | O'Brien Patrick | COO | G-Gift | Disposed | 540 | $0.00 |
| 8 Jan 2026 | O'Brien Patrick | COO | G-Gift | Disposed | 540 | $0.00 |